CN111758032A - 尿中酮体检测用试验片 - Google Patents
尿中酮体检测用试验片 Download PDFInfo
- Publication number
- CN111758032A CN111758032A CN201980014609.5A CN201980014609A CN111758032A CN 111758032 A CN111758032 A CN 111758032A CN 201980014609 A CN201980014609 A CN 201980014609A CN 111758032 A CN111758032 A CN 111758032A
- Authority
- CN
- China
- Prior art keywords
- urine
- test piece
- detecting
- ketone body
- oxidizing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 49
- 238000012360 testing method Methods 0.000 title claims abstract description 45
- 150000002576 ketones Chemical class 0.000 title claims abstract description 39
- 239000007800 oxidant agent Substances 0.000 claims abstract description 24
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical group [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 7
- 229940093930 potassium iodate Drugs 0.000 claims description 7
- 235000006666 potassium iodate Nutrition 0.000 claims description 7
- 239000001230 potassium iodate Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 9
- 229940083618 sodium nitroprusside Drugs 0.000 description 9
- 238000009535 clinical urine test Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- -1 alkali metal salt Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
在尿中酮体测定中，抑制起因于具有巯基的药剂的假阳性。通过向尿中酮体检测用试验片添加氧化剂，抑制起因于具有巯基的药剂的假阳性。
Description
【技术领域】
本发明涉及在尿中的酮体测定中的非特异反应的抑制。
【背景技术】
尿中的各种成分的检测在各种疾病、特别是肾疾病、尿路疾病、糖尿病的诊断中使用。尿受试体的采集对受试者的负担少，尿检查不仅是对于医院的受诊者，即使是被诊断为健康，也成为必须实施的检查。
在尿受试体的检查中使用的尿试验纸一般是将多个能由呈色反应检测尿中的各种成分的试验片贴附在PET等的合成树脂的支持体上的形状。将此尿试验纸浸到采集到纸杯等的尿受试体中后提起，目测确认试验片部分的呈色而定性(阳性、或者阴性)判断各种成分的有无。在用全自动分析装置检查时，向尿试验纸滴下尿受试体而光学检测试验片的呈色，应用于校准曲线而算出各种成分的浓度。
作为能用尿试验纸检测的项目，可举出葡萄糖、蛋白质、潜血、及酮体等。此外还能测定肌酸酐，也能随时从尿的蛋白质浓度算出一天的尿蛋白质量。
酮体是丙酮、乙酰醋酸、及β-羟基酪酸的总称，在健康人的尿中通常检测不到。但是，已知在糖尿病、甲状腺功能亢进症等中，尿中酮体成为阳性。
尿中酮体的检测原理利用了硝普钠与丙酮或乙酰醋酸反应而呈紫色。但是，硝普钠与具有巯基的化合物同样地反应而呈紫色。即，在受试者服用含具有巯基的化合物的药剂时，该药剂排出到尿中而与硝普钠反应，从而尿中酮体的检查结果成为假阳性。
作为这样的尿中酮体成为假阳性的具有巯基的药剂，已知卡托普利(降压剂)或布西拉明(抗类风湿剂)。特别是，由于作为布西拉明的副作用有蛋白尿，由于在布西拉明治疗患者中高频度地实施尿定性检查，尿中酮体成为假阳性成为问题。
【发明的概要】
【发明要解决的课题】
本发明要解决的课题以尿中酮体测定中起因于具有巯基的药剂的假阳性的抑制作为目的。
【用于解决课题的手段】
本发明人为解决上述课题而进行锐意探讨，从而完成以下的发明。
本发明提供以下的尿中酮体检测用试验片及假阳性抑制方法。
(1)尿中酮体检测用试验片，其含有氧化剂。
(2)(1)所述的尿中酮体检测用试验片，其中上述氧化剂是用于抑制假阳性的氧化剂。
(3)(1)或(2)所述的尿中酮体检测用试验片，其中氧化剂是碘酸钾。
(4)假阳性抑制方法，其特征在于，在尿中酮体检测用试验片上添加氧化剂，。
(5)(4)所述的假阳性抑制方法，其中氧化剂是碘酸钾。
【发明的效果】
本发明的尿中酮体检测用试验片由于含有氧化剂，即使在尿检查的受试者服用具有巯基的药剂时，也可抑制检查结果成为假阳性。
【具体实施方式】
本发明的尿中酮体检测用试验片如以下详细说明，作为含酮体检测用试剂的试验片制作。再者，可在支持体上有此外的检测对象项目的试验片而作为多项目检查用尿试验纸构成，也可作为仅检测尿中酮体的单项目的试验纸。
本发明的尿中酮体检测用试验片包含含有硝普钠和氧化剂的试剂组合物。在本发明的尿中酮体检测用试验片上，氧化剂硝普钠与具有巯基的化合物反应，由此可抑制非特异性地呈色而成为假阳性。作为氧化剂，不特别限定，可使用碘酸的碱金属盐或铁氰化钾。在这些氧化剂之中，优选碘酸钾。
本发明的尿中酮体检测用试验片通过调制含硝普钠和氧化剂的溶液，在使在吸收性载体中含浸之后使干燥而制作。溶液中的硝普钠的浓度优选设为0.5％～1.5％。另外，溶液中的氧化剂的浓度优选设为0.25％～0.75％。
作为负载在试验片上的试剂组合物，除了硝普钠、氧化剂之外，也可使用可溶化剂、增感剂、湿润剂或缓冲剂等。
作为使上述试剂组合物含浸的吸收性载体，多用滤纸，也能使用绵、无纺布、玻璃纤维等，也能使试剂组合物还含明胶、合成树脂等的有机聚合物。
将这样制造的尿中酮体检测用试验片贴附在支持体上，也可使得与检测此外的检测对象项目的试验片一同贴附到支持体上。作为支持体，能使用例如，由聚氯乙烯、聚对苯二甲酸乙二酯、聚丙烯、聚苯乙烯、聚酯等的塑料片构成的支持体。
将这样得到的试验纸浸到含尿的液体试样中，立即提起。进而，通过将一定时间后的呈色与预先制成的标准的色调表肉眼比较，进行试样的定性或半定量试验。或者，也能进行使用测定装置而光学测定反射率等，应用于校准曲线而求出浓度的定量试验。
【实施例】
【实施例1：含氧化剂的尿中酮体检测用试验片】
调制含0.8％硝普钠、0.4％碘酸钾、甘氨酸缓冲液(pH9.0)的尿中酮体检测用溶液，在使在滤纸中含浸之后使干燥而作为尿中酮体检测用试验片。
【比较例1：对照用尿中酮体检测用试验片】
除了不含碘酸钾之外，与实施例1同样地制作对照用尿中酮体检测用试验片。
【实施例2】
使用在实施例1、比较例1中制作的尿中酮体检测用试验片而测定尿受试体200例。在含氧化剂的试验片上是阴性、但在对照用试验片上成为阳性的受试体有25例。这25例的受试体的由酶法的酮体测定结果是0.0mg/dL(检测灵敏度以下)。另外，这25例的受试体全部是布西拉明服用中的类风湿性关节炎患者的尿。
【产业上的利用可能性】
本发明的尿中酮体检测用试验片由于含有氧化剂，可有效抑制起因于具有巯基的化合物的非特异性的反应。从而，在尿检查的受试者服用具有巯基的药剂时，也可抑制尿中酮体的检查结果成为假阳性。
Claims (5)
1.尿中酮体检测用试验片，其含有氧化剂。
2.权利要求1所述的尿中酮体检测用试验片，其中上述氧化剂是用于抑制假阳性的氧化剂。
3.权利要求1或2所述的尿中酮体检测用试验片，其中氧化剂是碘酸钾。
4.假阳性抑制方法，其特征在于，在尿中酮体检测用试验片上添加氧化剂。
5.权利要求4所述的假阳性抑制方法，其中氧化剂是碘酸钾。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018030561 | 2018-02-23 | ||
| JP2018-030561 | 2018-02-23 | ||
| PCT/JP2019/006596 WO2019163902A1 (ja) | 2018-02-23 | 2019-02-21 | 尿中ケトン体検出用試験片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111758032A true CN111758032A (zh) | 2020-10-09 |
Family
ID=67688101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980014609.5A Pending CN111758032A (zh) | 2018-02-23 | 2019-02-21 | 尿中酮体检测用试验片 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200378980A1 (zh) |
| EP (1) | EP3757573A4 (zh) |
| JP (1) | JP6803640B2 (zh) |
| CN (1) | CN111758032A (zh) |
| WO (1) | WO2019163902A1 (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147514A (en) * | 1977-11-21 | 1979-04-03 | Miles Laboratories, Inc. | Test means and method for detecting ketone bodies |
| JPS56125668A (en) * | 1980-03-06 | 1981-10-02 | Takeda Chem Ind Ltd | Pretreating method for specimen liquid and pretreating agent |
| US20020061563A1 (en) * | 2001-02-02 | 2002-05-23 | Stephens James Matthew | Apparatus and method for removing interfering substances from a urine sample using an oxidizing agent |
| US6699720B1 (en) * | 2000-05-26 | 2004-03-02 | Development Center For Biotechnology | Interference-eliminating membranes, test strips, kits and methods for use in uric acid assay |
| CN104089953A (zh) * | 2014-07-19 | 2014-10-08 | 青岛贝尔奥生物科技有限公司 | 一种快速测定尿巯基的方法 |
| CN104736717A (zh) * | 2012-11-02 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 试剂材料和有关的试验元件 |
| US20150306054A1 (en) * | 2012-11-20 | 2015-10-29 | Revive Therapeutics Inc. | The use of bucillamine in the treatment of gout |
| CN107365827A (zh) * | 2016-05-11 | 2017-11-21 | 杭州健昵福生物科技有限公司 | 一种将单磺酸四氮唑盐用于检测细胞活力的用途及方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5143796B2 (zh) * | 1973-11-08 | 1976-11-24 | ||
| JPS60233552A (ja) * | 1984-05-02 | 1985-11-20 | Terumo Corp | 試験片 |
| US5071769A (en) * | 1986-12-22 | 1991-12-10 | Abbott Laboratories | Method and device for ketone measurement |
| US4970172A (en) * | 1986-12-22 | 1990-11-13 | Abbott Laboratories | Method and device for ketone measurements |
| US5516700A (en) * | 1993-05-28 | 1996-05-14 | Chimera Research And Chemical, Inc. | Automated urinalysis method |
-
2019
- 2019-02-21 JP JP2019029198A patent/JP6803640B2/ja active Active
- 2019-02-21 EP EP19757269.6A patent/EP3757573A4/en not_active Withdrawn
- 2019-02-21 WO PCT/JP2019/006596 patent/WO2019163902A1/ja unknown
- 2019-02-21 CN CN201980014609.5A patent/CN111758032A/zh active Pending
-
2020
- 2020-08-19 US US16/997,153 patent/US20200378980A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147514A (en) * | 1977-11-21 | 1979-04-03 | Miles Laboratories, Inc. | Test means and method for detecting ketone bodies |
| JPS56125668A (en) * | 1980-03-06 | 1981-10-02 | Takeda Chem Ind Ltd | Pretreating method for specimen liquid and pretreating agent |
| US6699720B1 (en) * | 2000-05-26 | 2004-03-02 | Development Center For Biotechnology | Interference-eliminating membranes, test strips, kits and methods for use in uric acid assay |
| US20020061563A1 (en) * | 2001-02-02 | 2002-05-23 | Stephens James Matthew | Apparatus and method for removing interfering substances from a urine sample using an oxidizing agent |
| CN104736717A (zh) * | 2012-11-02 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 试剂材料和有关的试验元件 |
| US20150306054A1 (en) * | 2012-11-20 | 2015-10-29 | Revive Therapeutics Inc. | The use of bucillamine in the treatment of gout |
| CN104089953A (zh) * | 2014-07-19 | 2014-10-08 | 青岛贝尔奥生物科技有限公司 | 一种快速测定尿巯基的方法 |
| CN107365827A (zh) * | 2016-05-11 | 2017-11-21 | 杭州健昵福生物科技有限公司 | 一种将单磺酸四氮唑盐用于检测细胞活力的用途及方法 |
Non-Patent Citations (4)
| Title |
|---|
| MATSUKI, MIKI 等: "Evaluation of specificity of the modified urinary ketone body test strip", 《JAPANESE JOURNAL OF MEDICAL TECHNOLOGY》 * |
| 夏娟等: "快速血酮定量检测在糖尿病酮症诊治中的临床意义", 《实用糖尿病杂志》 * |
| 成凤桂等: "N-溴代丁二酰亚铵滴定法测定卡托普利", 《中南民族大学学报(自然科学版)》 * |
| 时惠敏等: "基于Fe~(2+)的显色反应测定还原性药物的研究进展", 《广州化工》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3757573A4 (en) | 2021-08-25 |
| JP2019144248A (ja) | 2019-08-29 |
| EP3757573A1 (en) | 2020-12-30 |
| JP6803640B2 (ja) | 2020-12-23 |
| WO2019163902A1 (ja) | 2019-08-29 |
| US20200378980A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lippi et al. | Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories | |
| CN1169533A (zh) | 用于测定血糖的试剂检验带 | |
| GB2435328A (en) | Indirectly detecting the presence of an analyte | |
| KR20180016512A (ko) | 혈액 검사 키트 및 혈액 분석 방법 | |
| JPH0629852B2 (ja) | 偏倚乾式分析要素を用いた液体試料中の被検物質の定量分析方法 | |
| CN102798726B (zh) | 维生素b12化学发光免疫定量检测试剂盒及其制备方法 | |
| EP2273269A1 (en) | Biosensor manufacturing method and biosensor | |
| CN104937106A (zh) | 用于监测生物流体的系统和方法 | |
| JP2022501604A (ja) | 診断アッセイの実行中のまたはそれに起因する、目的とするアナライトと関連するフック効果を検出する方法 | |
| JP4864615B2 (ja) | 多項目試験紙および検体中の被検物質の検出方法 | |
| JP3955911B2 (ja) | 尿中のアルブミン測定方法、尿中のアルブミン測定用指示薬、および尿中のアルブミン測定用試験片 | |
| CN109521200A (zh) | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 | |
| EP3221444A1 (en) | Lateral flow assay ratio test | |
| Cartier et al. | Toxic levels of acetaminophen produce a major positive interference on Glucometer Elite and Accu-chek Advantage glucose meters | |
| CN111758032A (zh) | 尿中酮体检测用试验片 | |
| CN106872379B (zh) | 一种尿液成分测量分析仪 | |
| US20180355402A1 (en) | Diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample | |
| US20180321202A1 (en) | Methods and devices for detecting methanol poisoning using formate oxidase | |
| Saibaba et al. | Interferences in clinical chemistry analysis | |
| US5776780A (en) | Method for quantitatively measuring white blood cells esterase activity in urine | |
| JPH0724599B2 (ja) | 体液のエステル分解作用及び／又はタンパク質分解作用を有する内容物を比色定量するための、担体に結合した多成分検出系 | |
| Datta | Methodological issues in point of care testing devices | |
| EP3404418A2 (en) | A diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample | |
| Supernatant et al. | Stability of reagent | |
| CZ30831U1 (cs) | Diagnostický proužek pro stanovení množství sarkosinu, kreatininu a peroxidu vodíku v biologickém nebo environmentálním vzorku |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201009 |
|
| RJ01 | Rejection of invention patent application after publication |